RxDoctor Payments Data

Justin Chan, MD

Family Medicine · Alhambra, CANPI 1003818501

Payments from drug & device makers

$13,341in general payments, 2019–2025

Across 299 payments — averaging $44.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Bayer$722
  • AbbVie$677
  • Amarin Pharma, Inc.$669
  • plus $6K from 42 others

What the payments were for

  • Travel & lodging$140%
  • Food & beverage$13,304100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,341 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$94,176
Medicare patients
329
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate127$78,291
FarxigaDapagliflozin Propanediol60$47,847
JardianceEmpagliflozin42$31,942
JanumetSitagliptin Phos/Metformin Hcl54$31,716
VascepaIcosapent Ethyl95$31,660
Diclofenac Sodium116$25,975
Cyclosporine49$21,459
VemlidyTenofovir Alafenamide13$17,175
OzempicSemaglutide14$15,203
Icosapent Ethyl64$11,507
TradjentaLinagliptin12$10,970
DapagliflozinDapagliflozin Propanediol12$9,516
RestasisCyclosporine14$8,655
ExelonRivastigmine12$8,097
Breo ElliptaFluticasone/Vilanterol15$5,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$62$110,007181 claims
AstraZenecaFarxiga$2,090$47,84760 claims
Boehringer IngelheimJardiance, Tradjenta$360$42,91154 claims
GileadVemlidy$2,363$17,17513 claims
Novo NordiskOzempic$213$15,20314 claims
GSKBreo Ellipta, Arnuity Ellipta$476$9,20232 claims
AbbVieRestasis$677$8,65514 claims
NovartisExelon$189$8,09712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →